| 高雄醫學大學 |
2002 |
Prognostic Factors in the Treatment of Osteosarcoma -- Review of 65 Cases in Recent 10 years
|
方璟文;簡松雄;林高田;林森源 |
| 國立臺灣大學 |
2009 |
Prognostic Factors in Women with Early Stage Small Cell Carcinoma of the Uterine Cervix
|
黃昭源; 陳宇立; 朱鐵吉; 鄭文芳; 謝長堯; 林明杰; HUANG, CHAO-YUAN; CHEN, YU-LI; CHU, TIEH-CHI; CHENG, WEN-FANG; HSIEH, CHANG-YAO; LIN, MING-CHIEH |
| 臺大學術典藏 |
2020-02-06T05:22:16Z |
Prognostic factors in women with early stage small cell carcinoma of the uterine cervix
|
Lin M.-C.;Hsieh C.-Y.;WEN-FANG CHENG;Chu T.-C.;Chen Y.-L.;Huang C.-Y.; Huang C.-Y.; Chen Y.-L.; Chu T.-C.; WEN-FANG CHENG; Hsieh C.-Y.; Lin M.-C.; Huang C.-Y.; Chen Y.-L.; Chu T.-C.; WEN-FANG CHENG; Hsieh C.-Y.; Lin M.-C. |
| 臺大學術典藏 |
2020-02-14T02:50:01Z |
Prognostic factors in women with early stage small cell carcinoma of the uterine cervix
|
Huang C.-Y.; Chen Y.-L.; Chu T.-C.; WEN-FANG CHENG; Hsieh C.-Y.; Lin M.-C. |
| 臺大學術典藏 |
2020-05-24T06:00:24Z |
Prognostic factors in women with early stage small cell carcinoma of the uterine cervix
|
Huang C.-Y.; YU-LI CHEN; Chu T.-C.; Cheng W.-F.; Hsieh C.-Y.; Lin M.-C. |
| 臺大學術典藏 |
2020-11-27T08:14:21Z |
Prognostic factors in women with early stage small cell carcinoma of the uterine cervix
|
Huang C.-Y.; Chen Y.-L.; Chu T.-C.; Cheng W.-F.; CHANG-YAO HSIEH; Lin M.-C. |
| 臺大學術典藏 |
2021-10-14T02:46:07Z |
Prognostic factors in women with early stage small cell carcinoma of the uterine cervix
|
CHAO-YUAN HUANG; Chen Y.-L.; Chu T.-C.; Cheng W.-F.; Hsieh C.-Y.; Lin M.-C. |
| 臺大學術典藏 |
2018-09-10T18:07:07Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang, S.-K. and Lee, M.-R. and Liao, W.-Y. and Ho, C.-C. and Ko, J.-C. and Shih, J.-Y.; MENG RUI LEE; Wei-Yu Liao; Chao-Chi Ho; Jin-Yuan Shih; JEN-CHUNG KO; SHENG-KAI LIANG |
| 臺大學術典藏 |
2019-03-04T08:06:47Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study
|
Sheng-Kai Liang;Meng-Rui Lee;Wei-Yu Liao;Chao-Chi Ho;Jen-Chung Ko;Jin-Yuan Shih; SHENG-KAI LIANG; MENG-RUI LEE; WEI-YU LIAO; CHAO-CHI HO; JEN-CHUNG KO; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-07-21T06:09:06Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.;Lee M.-R.;Wei-Yu Liao;Ho C.-C.;Ko J.-C.;Shih J.-Y.; Liang S.-K.; Lee M.-R.; WEI-YU LIAO; Ho C.-C.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-07-21T06:46:18Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Ko J.-C.; Shih J.-Y.; Liang S.-K.; Lee M.-R.; Liao W.-Y.; CHAO-CHI HO |
| 臺大學術典藏 |
2020-08-13T06:33:31Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.;Lee M.-R.;Liao W.-Y.;Ho C.-C.;Ko J.-C.;Jin-Yuan Shih; Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; Ko J.-C.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-08-12T02:50:39Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Shih J.-Y.; Ko J.-C.; CHAO-CHI HO; Liang S.-K.;Lee M.-R.;Liao W.-Y.;Chao-Chi Ho;Ko J.-C.;Shih J.-Y.; Liang S.-K.; Lee M.-R.; Liao W.-Y. |
| 臺大學術典藏 |
2021-01-08T03:40:20Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Shih J.-Y.; Ko J.-C.; Ho C.-C.; Liao W.-Y.; Lee M.-R.; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-03-11T07:58:28Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:29:34Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:34:19Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.;Lee M.-R.;Liao W.-Y.;Ho C.-C.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; MENG-RUI LEE; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T02:50:57Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.; MENG-RUI LEE; Liao W.-Y.; Ho C.-C.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:18Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
SHENG-KAI LIANG; Lee M.-R.; Liao W.-Y.; Ho C.-C.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-10-04T07:15:41Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2018 |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liao W.-Y.; MENG-RUI LEE; Liang S.-K.; Ho C.-C.; Ko J.-C.; Shih J.-Y. |
| 國立臺灣大學 |
2006 |
Prognostic Factors of Anaplastic Thyroid Carcinoma
|
曾芬郁; TSENG, FEN-YU |
| 臺大學術典藏 |
2013-10 |
Prognostic Factors of Bile Duct Cancers in Patients Receiving Pretreatment FDG PET/CT.
|
RUOH-FANG YEN; RUOH-FANG YEN |
| 中國醫藥大學 |
2003-08-30 |
Prognostic Factors of Biochemical Failure after Radical Prostatectomy.
|
謝登富(DENG-FU HSIEH); 吳錫金(Wu,His-Chin); 張兆祥(Chang,Chao-Hsian); 陳汶吉(Chen,Wen-Chi); 陳昶仲(Chang-Chung Chen); 鄒頡龍; 陳國樑 |
| 淡江大學 |
2023-10-27 |
Prognostic Factors of Cirrhotic Patients with Invasive Fungal Infections
|
Hung, Tsung-Hsing;Ko, Ping-Hung;Tsai, Chih-Chun;Wang, Chih-Ying;Lee, Hsing-Feng |
